Archives
-
4-Hydroxytamoxifen: Practical Protocol Guide
2026-08-23
4-Hydroxytamoxifen (SKU B6167) provides a DMSO-compatible estrogen receptor modulator for breast cancer research, prostate cancer research, apoptosis assays, and cardiac myocyte calcium handling studies. It should not be selected for workflows requiring aqueous or ethanol dissolution, and prepared solutions should not be stored long term.
-
MK-4827 (Niraparib) for PARP Research
2026-08-22
MK-4827 (Niraparib) gives cancer researchers a selective PARP-1/-2 inhibition workflow for testing DNA repair vulnerability, BRCA-associated sensitivity, and rational combination treatments. This guide connects dose-response experiments with spliceosome-focused hepatocellular carcinoma models, radiosensitization, and resistance studies.
-
EDC.HCl: Practical Coupling Workflow
2026-08-22
EDC.HCl is a water-soluble carbodiimide used to activate carboxyl groups for amide bond formation in peptide synthesis, bioconjugation, and related in vitro workflows. It should be handled as a laboratory reagent only; the product dossier reports no in vivo or clinical data.
-
DMXAA (Vadimezan): Assay Reliability Guide
2026-08-21
A scenario-driven guide to using DMXAA (Vadimezan), SKU A8233, in viability, proliferation, apoptosis, and endothelial assays. It connects formulation control, dose selection, mechanism-aware interpretation, and practical vendor evaluation for more consistent cancer biology research.
-
Astrocyte Heterogeneity Across Space and Time
2026-08-20
Schroeder et al. establish a cross-species, developmental transcriptomic atlas showing that astrocytes retain strong regional identities while substantially remodeling those signatures after birth. The study connects molecular regionalization with astrocyte morphology and provides a framework for validating spatially restricted markers in mouse and marmoset brain tissue.
-
Sulfo-Cy3 NHS Ester for Vascular Assays
2026-08-20
Learn how this hydrophilic fluorescent dye supports aqueous protein conjugation, uptake assays, and imaging workflows relevant to collateral-vessel biology. The guide combines practical labeling parameters with controls inspired by the AIBP-LRP2-HDL-miR-223-CXCR4 mechanism.
-
WEHI-539: Mapping BCL-XL Apoptotic Dependency
2026-08-19
WEHI-539 is a selective BCL-XL inhibitor for resolving mitochondrial apoptotic dependencies rather than simply measuring cytotoxicity. This article connects its biochemical selectivity with MCL-1 enhancer biology, assay design, and cancer stem cell sensitization.
-
BMS 599626 Dihydrochloride: EGFR/HER2 Inhibition
2026-08-19
BMS 599626 dihydrochloride is an EGFR and ErbB2 inhibitor with reported nanomolar kinase activity and dose-dependent suppression of receptor phosphorylation. Its preclinical profile supports breast cancer research, lung cancer research, and mechanistic studies of HER1/HER2 signaling, but it does not establish clinical efficacy or senolytic activity.
-
TIA1–CLSTN1 Splicing Drives Breast Cancer Metastasis
2026-08-18
A 2026 Oncogene study identifies a DAPK3–TIA1–CLSTN1 regulatory axis that connects alternative splicing with epithelial-to-mesenchymal transition and breast cancer metastasis. The work also develops splice-switching antisense oligonucleotides that reverse CLSTN1 exon 11 inclusion, providing a mechanistic and therapeutic framework for targeting pro-metastatic RNA processing.
-
Potassium Iodide (KI): Research Facts and Limits
2026-08-18
Potassium Iodide, also written KI, supplies iodide for thyroid hormone synthesis and can support radioactive iodine thyroid blocking under appropriate public-health guidance. The B2008 research product has documented solubility, storage, and purity specifications, but the cited immunotherapy study does not establish KI as an immunotherapy component.
-
Fumagillin Beyond the Product Page: MetAP-2 Strategy
2026-08-17
A translational perspective on Fumagillin as a methionine aminopeptidase-2 inhibitor, connecting endothelial cell proliferation inhibition and tumor-induced angiogenesis inhibition with exploratory antiparasitic research while emphasizing assay design, compound handling, evidence maturity, and responsible cross-domain interpretation.
-
Tolazoline, KATP Channels, and Insulin Release
2026-08-17
The 1992 Br. J. Pharmacol. study showed that Tolazoline and related imidazoline antagonists increase insulin release primarily by inhibiting ATP-sensitive K+ channels in pancreatic β-cells, rather than simply by blocking α2-adrenoceptors. Its combined use of 86Rb efflux, whole-cell patch clamp, and pharmacological challenge assays provides a useful framework for interpreting insulin secretion modulation in islet experiments.
-
PF-562271 HCl: A Kinome-Aware Assay Strategy
2026-08-16
PF-562271 HCl is a selective FAK/Pyk2 inhibitor for cancer research and pathway-focused pharmacology. This guide connects its biochemical profile with a cheminformatics-informed strategy for choosing orthogonal assays, interpreting selectivity, and avoiding misleading cellular conclusions.
-
Purmorphamine: Reliable Smoothened Assay Workflows
2026-08-15
This scenario-based guide explains how Purmorphamine, SKU A8228, can improve interpretation of viability, proliferation, cytotoxicity, and osteogenic differentiation experiments through disciplined pathway controls and formulation-aware dosing. It connects product specifications with published Smoothened biology while outlining practical limits for cross-species translation and vendor selection.
-
Meropenem Trihydrate: A Resistance-Phenotyping Lens
2026-08-14
Meropenem trihydrate is more than a broad-spectrum carbapenem antibiotic: it can anchor rigorous studies of susceptibility, resistance biology, and metabolomic phenotype. This guide connects meropenem assay design with 2025 LC-MS/MS evidence on carbapenemase-producing Enterobacterales.